Palantir is expanding its role in the UK healthcare sector with a new training initiative. However, analysts warn that the expectations of the AI specialist could be too high.
• Palantir and Multiverse are developing FDP-related training programs for tens of thousands of NHS staff
• Analyst warns market is overestimating future demand despite strong Q3, according to GuruFocus
• Stock slightly weaker after rally; Analyst assessments remain mixed
Palantir and Multiverse advance training in the NHS
Palantir and the British education platform Multiverse are launching new training programs for employees in the NHS. According to the joint announcement, the programs specifically tailored to the Federated Data Platform are intended to help train staff in the use of data and AI.
The FDP, provided by Palantir, connects previously disparate systems and is already helping dozens of NHS trusts achieve more efficient operations and reduce waiting times. According to Palantir, the platform has enabled additional operations and reduced delays in layoffs, among other benefits. The first training cohorts are scheduled to begin at the beginning of 2026.
Analyst warns against excessive expectations
Despite the positive operational development, part of the market advises caution. A report from GuruFocus shows that Freedom Capital Markets analyst Almas Almaganbetov raised his price target, but still rated the valuation as ambitious.
While Palantir delivered strong revenue growth and a high operating margin in the third quarter, Almaganbetov said the stock could be vulnerable to disappointment if commercial growth normalizes or higher costs slow profitability.
This is how the share moves in the market
After the latest developments, the market initially reacted cautiously: in NASDAQ trading, shares were temporarily down 1.32 percent at $171.71. Since the beginning of the year there has been a strong increase of more than 130 percent.
However, analyst sentiment remains mixed. According to TipRanks, there are 16 assessments, including three buy, eleven hold and two sell recommendations. The average price target is $187.87 and implies an upside potential of around eight percent.
Long-term opportunities, short-term valuation risks
The cooperation with the NHS could strengthen Palantir’s position in the European healthcare sector and further expand the use of its own platform. According to the statement, the training offensive underlines that the successful deployment of the FDP depends largely on trained personnel.
At the same time, observers like Almaganbetov point to the high expectations that are already priced into the share price. What remains crucial for investors is whether Palantir can maintain its commercial growth momentum and meet its ambitious forecasts.
Editorial team finanzen.net
By the way: Palantir and other US stocks can even be traded on finanzen.net ZERO until 11 p.m. (without order fees, plus spreads). Open a depot now for free and secure a new customer bonus!
Selected leveraged products on Palantir
With knock-outs, speculative investors can participate disproportionately in price movements. Simply select the lever you want and we will show you suitable open-end products on Palantir
The leverage must be between 2 and 20
Advertising